Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

Status Completed

Clinical Trial Summary

This is a multi-center, randomized, parallel study to evaluate effect of exenatide on 24h-UAER in patients with diabetic nephropathy.

Screening will be made to select eligible participants before intervention. The trial will include 2-week run-in period of stable doses of glargine plus lispro insulin and 24-week treatment period. After the run-in period, patients were randomly assigned to one of two groups for antihyperglycaemic therapies for a total of 24-weeks: glargine plus exenatide and continued glargine plus lispro insulin. The treatment of exenatide will be initiated by 5ug bid, and uptitrated to 10 ug bid after 4 weeks and then maintained at 10ug bid until the completion of the study. Lispro insulin will be initially treated according to the insulin dosage of previous antihyperglycaemic therapies, and further titrated up at 4-week intervals until to reach the target fasting blood glucose (FPG).

Clinical Trial Description

Objective:

To evaluate effect of exenatide on 24-UAER in patients with diabetic nephropathy

Hypothesis:

Compared with glargine plus lispro group, at 24 weeks, glargine plus exenatide group can: 1) take more significant reduction of 24h-UAER; 2) take more reduction of ACR; 3) take more weight loss, blood pressure reduction; 4) take lower hypoglycemia incidence and less insulin dosage.

Primary endpoint： The proportion of reduction of 24h-UAER(urinary albumin excretion rates)

Secondary endpoints： 24h-UAER at 24 weeks; the rate of urinary albumin to creatinine ratio(ACR) change at 24 weeks; HbA1c, FPG,PPG, weight , BP

Treatment duration： 24weeks

Patient/Sites： 90 patients / 3 sites

Timeline (best case)： Planed duration of recruitment period: 6 month Planed date for first screening: 1 October 2015 Planed completion of the last subject: 1 March 2017 Planned completion of clinical trial report: 30 October 2017 ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02690883
Study type	Interventional
Source	Nanfang Hospital of Southern Medical University
Contact
Status	Completed
Phase	Phase 4
Start date	April 8, 2016
Completion date	December 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05530356` - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Terminated	`NCT01575379` - A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes	Phase 4
Active, not recruiting	`NCT05656963` - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Not yet recruiting	`NCT04084886` - TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
Active, not recruiting	`NCT04869761` - Stem Cell Therapy for Chronic Kidney Disease	Phase 1
Recruiting	`NCT04570735` - MRI Biomarkers in Diabetic Kidney Disease
Completed	`NCT03165240` - This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated	Phase 1
Completed	`NCT01968668` - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)	Phase 2
Completed	`NCT02552277` - A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy	Phase 2
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Terminated	`NCT02410005` - Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)	Phase 2/Phase 3
Unknown status	`NCT01918488` - Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease	N/A
Completed	`NCT00915200` - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy	Phase 2
Completed	`NCT03165227` - This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)	Phase 1
Active, not recruiting	`NCT04531163` - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy	Phase 2/Phase 3
Active, not recruiting	`NCT03620773` - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes	Phase 1/Phase 2
Completed	`NCT03618420` - Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function	Phase 1/Phase 2
Not yet recruiting	`NCT03284996` - Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.	N/A
Completed	`NCT03334318` - PERL Continuous Glucose Monitoring (CGM) Study
Completed	`NCT04380584` - Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.